Ascendis Pharma Reports Sustained Efficacy of Yorvipath Over Five Years
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
Source: seekingalpha
- Sustained Efficacy: Ascendis Pharma's adult hypoparathyroidism treatment Yorvipath (palopegteriparatide) demonstrated sustained efficacy in a five-year phase 2 trial, with 82% of patients achieving serum calcium levels within the normal range at week 266, indicating the treatment's effectiveness in improving patient health.
- Multi-System Impact: The hormone replacement therapy showed a balanced and beneficial impact on key target organ systems—kidneys, small intestine, CNS, and bones—evidenced by normalized and stable urine calcium, serum calcium, quality of life, and bone mineral density, highlighting its therapeutic potential across multiple dimensions.
- Trial Design: The PaTH Forward trial enrolled 59 participants, who underwent a four-week randomized, double-blind, placebo-controlled period followed by a 262-week open-label extension, with only 3 patients not completing the five-year study, demonstrating good tolerability and engagement.
- Market Outlook: As Ascendis Pharma enters a growth phase, its potential in the rare endocrine drug market is widely recognized, which is expected to enhance its future market performance and investment appeal.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASND
Wall Street analysts forecast ASND stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 231.150
Low
240.00
Averages
277.08
High
342.00
Current: 231.150
Low
240.00
Averages
277.08
High
342.00
About ASND
Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ascendis Pharma Reports Three-Year Data on TransCon PTH Efficacy
- Sustained Long-term Efficacy: In the three-and-a-half-year PaTHway trial, TransCon PTH demonstrated an 86% response rate for the multi-component endpoint, successfully replicating endogenous parathyroid hormone actions and significantly improving patients' quality of life.
- Independence from Conventional Therapy: The trial showed that 100% of patients achieved independence from active vitamin D, and 96% maintained calcium intake below 600 mg/day, indicating TransCon PTH's effective replacement of traditional therapies.
- Improved Kidney Function: At Week 182, the mean estimated glomerular filtration rate (eGFR) reached 80.2 mL/min/1.73 m², reflecting an increase of 11.0 mL/min/1.73 m² from baseline, showcasing TransCon PTH's positive impact on renal function.
- Good Safety Profile: Throughout the trial, TransCon PTH was well-tolerated with no new safety signals identified, and all adverse events were mild or moderate, ensuring patient safety during treatment.
See More
Ascendis Pharma Reports Five-Year Data on TransCon PTH for Hypoparathyroidism
- Sustained Efficacy: Ascendis Pharma's TransCon PTH demonstrated sustained efficacy in the five-year Phase 2 trial, with 82% of patients achieving normal serum calcium levels by Week 266 without active vitamin D, indicating its potential as a new standard of care for hypoparathyroidism.
- Kidney Function Improvement: The trial showed a sustained increase in mean eGFR from baseline, reflecting the therapy's effectiveness in improving calcium levels while countering age-related kidney function decline, thereby enhancing patients' quality of life.
- Stable Bone Density: Bone mineral density scores were corrected early and remained stable over five years, highlighting TransCon PTH's long-term benefits for bone health and reinforcing its position as a new standard treatment for chronic hypoparathyroidism.
- Good Safety Profile: The therapy was generally well tolerated with no new safety signals identified; most adverse events were mild or moderate, and no patients discontinued treatment, demonstrating the safety and efficacy of TransCon PTH.
See More
Ascendis Pharma Reports Sustained Efficacy of Yorvipath Over Five Years
- Sustained Efficacy: Ascendis Pharma's adult hypoparathyroidism treatment Yorvipath (palopegteriparatide) demonstrated sustained efficacy in a five-year phase 2 trial, with 82% of patients achieving serum calcium levels within the normal range at week 266, indicating the treatment's effectiveness in improving patient health.
- Multi-System Impact: The hormone replacement therapy showed a balanced and beneficial impact on key target organ systems—kidneys, small intestine, CNS, and bones—evidenced by normalized and stable urine calcium, serum calcium, quality of life, and bone mineral density, highlighting its therapeutic potential across multiple dimensions.
- Trial Design: The PaTH Forward trial enrolled 59 participants, who underwent a four-week randomized, double-blind, placebo-controlled period followed by a 262-week open-label extension, with only 3 patients not completing the five-year study, demonstrating good tolerability and engagement.
- Market Outlook: As Ascendis Pharma enters a growth phase, its potential in the rare endocrine drug market is widely recognized, which is expected to enhance its future market performance and investment appeal.
See More
Ascendis Pharma to Present New Data at ENDO 2026
- Clinical Data Sharing: Ascendis Pharma will present the latest clinical trial data on hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency through two oral presentations and three posters at the 2026 ENDO meeting, showcasing the potential of its innovative therapies.
- Key Research Findings: At the conference, Ascendis will highlight the long-term safety and efficacy of TransCon PTH, based on results from multiple clinical trials, emphasizing its application prospects in treating patients with hypoparathyroidism.
- Advancements in Achondroplasia Treatment: Ascendis will also present 52-week results of Navepegritide combined with Lonapegsomatropin for treating children with achondroplasia, further validating its potential to improve patient growth and quality of life.
- Global Impact: This presentation not only enhances Ascendis' leadership position in rare endocrine diseases but may also attract more investor attention to its innovative technology platform, driving future business growth.
See More
Siren Fully Liquidates Ascendis Pharma Holdings
- Liquidation Transaction: On May 14, 2026, Siren disclosed in an SEC filing that it sold its entire holding of 235,862 shares of Ascendis Pharma A/S, with an estimated transaction value of $52.87 million, reflecting a cautious outlook on the company's future prospects.
- Position Change: This sale resulted in a $50.30 million decrease in Siren's quarter-end position in Ascendis, which includes both the sale and price effects, indicating market reactions to the stock's performance.
- Company Performance: As of May 13, 2026, Ascendis Pharma's stock was priced at $243.58, up 50% over the past year and outperforming the S&P 500 by 24 percentage points, highlighting its market appeal in the rare disease sector.
- Financial Status: Ascendis Pharma reported first-quarter revenues exceeding €247 million, primarily driven by €197 million in YORVIPATH sales, although its net income fluctuated significantly due to the recognition of a deferred tax asset, raising questions about its ability to achieve sustainable cash flow growth in the future.
See More
Ascendis Pharma to Announce Q1 Earnings on May 7
- Earnings Announcement Schedule: Ascendis Pharma A/S is set to release its Q1 2023 earnings report on May 7 before market open, with a consensus EPS estimate of -$0.17, indicating challenges in profitability.
- Revenue Expectations: Analysts estimate revenue at $315.79 million, reflecting cautious market sentiment regarding the company's product sales and market performance, which could impact investor confidence.
- Historical Financial Data: Historical financial data for Ascendis Pharma A/S will provide investors with crucial context to assess performance trends and future growth potential, especially in the increasingly competitive biopharmaceutical sector.
- Market Reaction Anticipation: As the earnings report approaches, market reactions to Ascendis Pharma may be influenced by the comparison of actual results to expectations, prompting investors to closely monitor stock price fluctuations post-announcement.
See More
Ascendis Pharma Reports Three-Year Data on TransCon PTH Efficacy
- Sustained Long-term Efficacy: In the three-and-a-half-year PaTHway trial, TransCon PTH demonstrated an 86% response rate for the multi-component endpoint, successfully replicating endogenous parathyroid hormone actions and significantly improving patients' quality of life.
- Independence from Conventional Therapy: The trial showed that 100% of patients achieved independence from active vitamin D, and 96% maintained calcium intake below 600 mg/day, indicating TransCon PTH's effective replacement of traditional therapies.
- Improved Kidney Function: At Week 182, the mean estimated glomerular filtration rate (eGFR) reached 80.2 mL/min/1.73 m², reflecting an increase of 11.0 mL/min/1.73 m² from baseline, showcasing TransCon PTH's positive impact on renal function.
- Good Safety Profile: Throughout the trial, TransCon PTH was well-tolerated with no new safety signals identified, and all adverse events were mild or moderate, ensuring patient safety during treatment.
See More
Ascendis Pharma Reports Five-Year Data on TransCon PTH for Hypoparathyroidism
- Sustained Efficacy: Ascendis Pharma's TransCon PTH demonstrated sustained efficacy in the five-year Phase 2 trial, with 82% of patients achieving normal serum calcium levels by Week 266 without active vitamin D, indicating its potential as a new standard of care for hypoparathyroidism.
- Kidney Function Improvement: The trial showed a sustained increase in mean eGFR from baseline, reflecting the therapy's effectiveness in improving calcium levels while countering age-related kidney function decline, thereby enhancing patients' quality of life.
- Stable Bone Density: Bone mineral density scores were corrected early and remained stable over five years, highlighting TransCon PTH's long-term benefits for bone health and reinforcing its position as a new standard treatment for chronic hypoparathyroidism.
- Good Safety Profile: The therapy was generally well tolerated with no new safety signals identified; most adverse events were mild or moderate, and no patients discontinued treatment, demonstrating the safety and efficacy of TransCon PTH.
See More
Ascendis Pharma Reports Sustained Efficacy of Yorvipath Over Five Years
- Sustained Efficacy: Ascendis Pharma's adult hypoparathyroidism treatment Yorvipath (palopegteriparatide) demonstrated sustained efficacy in a five-year phase 2 trial, with 82% of patients achieving serum calcium levels within the normal range at week 266, indicating the treatment's effectiveness in improving patient health.
- Multi-System Impact: The hormone replacement therapy showed a balanced and beneficial impact on key target organ systems—kidneys, small intestine, CNS, and bones—evidenced by normalized and stable urine calcium, serum calcium, quality of life, and bone mineral density, highlighting its therapeutic potential across multiple dimensions.
- Trial Design: The PaTH Forward trial enrolled 59 participants, who underwent a four-week randomized, double-blind, placebo-controlled period followed by a 262-week open-label extension, with only 3 patients not completing the five-year study, demonstrating good tolerability and engagement.
- Market Outlook: As Ascendis Pharma enters a growth phase, its potential in the rare endocrine drug market is widely recognized, which is expected to enhance its future market performance and investment appeal.
See More
Ascendis Pharma to Present New Data at ENDO 2026
- Clinical Data Sharing: Ascendis Pharma will present the latest clinical trial data on hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency through two oral presentations and three posters at the 2026 ENDO meeting, showcasing the potential of its innovative therapies.
- Key Research Findings: At the conference, Ascendis will highlight the long-term safety and efficacy of TransCon PTH, based on results from multiple clinical trials, emphasizing its application prospects in treating patients with hypoparathyroidism.
- Advancements in Achondroplasia Treatment: Ascendis will also present 52-week results of Navepegritide combined with Lonapegsomatropin for treating children with achondroplasia, further validating its potential to improve patient growth and quality of life.
- Global Impact: This presentation not only enhances Ascendis' leadership position in rare endocrine diseases but may also attract more investor attention to its innovative technology platform, driving future business growth.
See More
Siren Fully Liquidates Ascendis Pharma Holdings
- Liquidation Transaction: On May 14, 2026, Siren disclosed in an SEC filing that it sold its entire holding of 235,862 shares of Ascendis Pharma A/S, with an estimated transaction value of $52.87 million, reflecting a cautious outlook on the company's future prospects.
- Position Change: This sale resulted in a $50.30 million decrease in Siren's quarter-end position in Ascendis, which includes both the sale and price effects, indicating market reactions to the stock's performance.
- Company Performance: As of May 13, 2026, Ascendis Pharma's stock was priced at $243.58, up 50% over the past year and outperforming the S&P 500 by 24 percentage points, highlighting its market appeal in the rare disease sector.
- Financial Status: Ascendis Pharma reported first-quarter revenues exceeding €247 million, primarily driven by €197 million in YORVIPATH sales, although its net income fluctuated significantly due to the recognition of a deferred tax asset, raising questions about its ability to achieve sustainable cash flow growth in the future.
See More
Ascendis Pharma to Announce Q1 Earnings on May 7
- Earnings Announcement Schedule: Ascendis Pharma A/S is set to release its Q1 2023 earnings report on May 7 before market open, with a consensus EPS estimate of -$0.17, indicating challenges in profitability.
- Revenue Expectations: Analysts estimate revenue at $315.79 million, reflecting cautious market sentiment regarding the company's product sales and market performance, which could impact investor confidence.
- Historical Financial Data: Historical financial data for Ascendis Pharma A/S will provide investors with crucial context to assess performance trends and future growth potential, especially in the increasingly competitive biopharmaceutical sector.
- Market Reaction Anticipation: As the earnings report approaches, market reactions to Ascendis Pharma may be influenced by the comparison of actual results to expectations, prompting investors to closely monitor stock price fluctuations post-announcement.
See More
